Reaction
Haptoglobin Decreased reporting signals
As of the last recalculation, Haptoglobin Decreased appears in 790 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 161.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 235 | 161.8 | 162.5 |
| Ravulizumab | 35 | 71.4 | 71.5 |
| Anti-Thymocyte Globulin (Rabbit) | 13 | 43.2 | 43.2 |
| Basiliximab | 13 | 29.6 | 29.6 |
| Busulfan | 15 | 25.6 | 25.6 |
| Blinatumomab | 6 | 15.3 | 15.3 |
| Deferasirox | 10 | 10.1 | 10.1 |
| Sevelamer Carbonate | 4 | 9.2 | 9.2 |
| Carfilzomib | 8 | 7.5 | 7.5 |